CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S363
DOI: 10.1055/s-0038-1640978
Abstracts
Schlafmedizin: Sleeping Disorders

Clinical and economic benefit of upper airway stimulation for obstructive sleep apnea in the German setting

AK Weschenfelder
1   Universität Duisburg-Essen, Essen
,
JB Pietzsch
2   Wing Tech Inc., Menlo Park, USA
,
W Randerath
3   Klinik für Pneumologie und Allergologie, Krankenhaus Bethanien, Solingen
,
A Steffen
4   Klinik für Hals-Nasen- und Ohrenheilkunde, Universitätsklinikum Schleswig-Holste, Lübeck
,
S Liu
2   Wing Tech Inc., Menlo Park, USA
,
B Geisler
2   Wing Tech Inc., Menlo Park, USA
,
J Wasem
5   Lehrstuhl für Medizinmanagement, Universität Duisburg-Essen, Essen
,
J Biermann-Stallwitz
5   Lehrstuhl für Medizinmanagement, Universität Duisburg-Essen, Essen
› Author Affiliations
Inspire Medical Systems, Inc.
› Further Information
Also available at
 
 

    Introduction:

    Upper airway stimulation (UAS) is a treatment approach intended for patients with medium-to-severe obstructive sleep apnea who have failed or cannot tolerate continuous positive airway pressure therapy. Our objective was to evaluate the clinical and economic benefit of UAS in the German social health insurance.

    Methods:

    A Markov model projected the probabilities of hypertension, myocardial infarction (MI), stroke, and motor vehicle collisions (MVC) to estimate cardiovascular and all-cause mortality, quality-adjusted life years (QALYs), and total direct costs for UAS versus no treatment from a payer perspective. Baseline characteristics and treatment efficacy were obtained from a German prospective observational study and literature. Ten-year relative event risks (RR) and lifetime survival benefit were computed as well as well as incremental cost-effectiveness ratios in Euros per QALY.

    Results:

    According to the observational study the patients' (mean age 57 years, BMI 29 kg/m2) apnea-hypopnea index was reduced from 31.2 to 13.8 events per hour by UAS compared to no treatment. UAS reduced all types of events projected (ten-year RR for stroke, MI, cardiovascular death, and MVC: 0.76, 0.64, 0.65, and 0.34, respectively) and increased survival by 1.27 life years. While the UAS strategy incurred an additional 1.02 QALYs, there were also additional mean costs of 54,578 Euros over the patient's lifetime, resulting in an incremental cost-effectiveness ratio of € 53,698 per QALY gained.

    Conclusions:

    Upper airway stimulation adds meaningful benefit to endpoints relevant to obstructive sleep apnea patients and is a cost-effective therapy for patients ineligible to continuous positive pressure ventilation in the German healthcare setting.


    #

    No conflict of interest has been declared by the author(s).

    Ann-Kathrin Weschenfelder
    Lehrstuhl für Medizinmanagement, Universität Duisburg-Essen,
    Thea-Leymann-Str. 9, 45127,
    Essen

    Publication History

    Publication Date:
    18 April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York